{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:47:24Z","timestamp":1788583644396,"version":"build-2803163510"},"reference-count":84,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPR"],"DOI":"10.2147\/jpr.s457982","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T10:02:35Z","timestamp":1717581755000},"page":"1989-2000","source":"Crossref","is-referenced-by-count":3,"title":["Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access"],"prefix":"10.2147","volume":"Volume 17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8609-9424","authenticated-orcid":true,"given":"Lynn","family":"Webster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Gudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1097\/j.pain.0000000000001939","volume":"161","author":"Raja","year":"2020","journal-title":"Pain"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.15585\/mmwr.mm7215a1","volume":"72","author":"Rikard","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"ref4","unstructured":"US Food and Drug Administration. Center for drug evaluation and research. General principles for evaluating the abuse deterrence of generic solid oral opioid drug products guidance for industry. Available from: https:\/\/www.fda.gov\/media\/96643\/download. Accessed July 24, 2023."},{"key":"ref5","unstructured":"Data Analysis & Resources. US center for disease control and prevention; 2022. Available from: https:\/\/www.cdc.gov\/opioids\/data\/analysis-resources.html. Accessed July 24, 2023."},{"key":"ref6","unstructured":"Provisional drug overdose death counts. US center for disease control and prevention; 2023. Available from: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed July 24, 2023."},{"key":"ref7","unstructured":"The economic toll of the opioid crisis reached nearly $1.5 trillion in 2020. Joint Economic Committee. Available from: https:\/\/www.jec.senate.gov\/public\/index.cfm\/democrats\/2022\/9\/the-economic-toll-of-the-opioid-crisis-reached-nearly-1-5-trillion-in-2020. Accessed April 28, 2023."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"108350","DOI":"10.1016\/j.drugalcdep.2020.108350","volume":"218","author":"Florence","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1213\/ANE.0000000000002496","volume":"125","author":"Webster","year":"2017","journal-title":"Anesth Analg"},{"key":"ref10","unstructured":"Dydyk AM, Jain NK, Gupta M Opioid use disorder. StatPearls Publishing; 2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK553166\/#. Accessed December 1, 2023."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.31887\/DCNS.2017.19.3\/wberrettini","volume":"19","author":"Berrettini","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174294","volume":"20","author":"Wang","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e0251502","DOI":"10.1371\/journal.pone.0251502","volume":"16","author":"Hernandez","year":"2021","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.drugalcdep.2018.12.030","volume":"197","author":"Jones","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jad.2018.04.058","volume":"235","author":"Feingold","year":"2018","journal-title":"J Affect Disord"},{"key":"ref16","unstructured":"Institute for Clinical and Economic Review. Draft evidence report\u2014abuse deterrent formulations of opioids: effectiveness and value. Available from: http:\/\/icerorg.wpengine.com\/wp-content\/uploads\/2020\/10\/NECEPAC_ADF_Final_Report_08_08_17.pdf. Accessed December 11, 2023."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.21r03223","volume":"25","author":"Konakanchi","year":"2023","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21926\/obm.geriatr.1902047","volume":"3","author":"Pergolizzi","year":"2019","journal-title":"OBM Geriatric"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s40266-021-00893-z","volume":"38","author":"Dufort","year":"2021","journal-title":"Drugs Aging"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/AJP.0000000000000708","volume":"35","author":"Eisdorfer","year":"2019","journal-title":"Clin J Pain"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2387","volume":"139","author":"McCabe","year":"2017","journal-title":"Pediatrics"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e214552","DOI":"10.1001\/jamanetworkopen.2021.4552","volume":"4","author":"Wilson","year":"2021","journal-title":"JAMA Network Open"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1111\/add.15487","volume":"116","author":"Hadland","year":"2021","journal-title":"Addiction"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/17425255.2020.1721458","volume":"16","author":"Balyan","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/JMDH.S38562","volume":"6","author":"Brennan","year":"2013","journal-title":"J Multidiscip Healthc"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5055\/jom.2020.0559","volume":"16","author":"Gudin","year":"2020","journal-title":"J Opioid Manag"},{"key":"ref27","unstructured":"XTAMPZA\u00ae ER (oxycodone) extended-release capsules [package insert]. Collegium Pharmaceutical, Inc; 2021."},{"key":"ref28","unstructured":"MS CONTIN\u00ae (morphine sulfate extended-release tablets), for oral use, CII. [package insert]. Purdue Pharma, LP; 2021."},{"key":"ref29","unstructured":"OXYCONTIN\u00ae (oxycodone hydrochloride) extended-release tablets, for oral use, CII. [package insert]. Purdue Pharma, LP; 2021."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jpain.2014.04.008","volume":"15","author":"Yu","year":"2014","journal-title":"J Pain"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/00325481.2016.1134022","volume":"128","author":"Taber","year":"2016","journal-title":"Postgrad Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clinthera.2009.02.019","volume":"31","author":"Peniston","year":"2009","journal-title":"Clin Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jpainsymman.2011.12.280","volume":"44","author":"Nalamachu","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"e0167499","DOI":"10.1371\/journal.pone.0167499","volume":"11","author":"Iwanicki","year":"2016","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/pme.12194","volume":"14","author":"Webster","year":"2013","journal-title":"Pain Med"},{"key":"ref36","volume-title":"Essentials of Pain Medicine","year":"2018"},{"key":"ref37","unstructured":"Veterans Affairs & Department of Defense. VA\/DoD Clinical practice guideline for opioid therapy for pain. Available from: https:\/\/www.healthquality.va.gov\/guidelines\/Pain\/cot\/VADoDOTCPG022717.pdf. Accessed July 24, 2023."},{"key":"ref38","unstructured":"National Academies of Sciences. Engineering, and Medicine. Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use. Washington, DC: The National Academies Press; 2017."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/00325481.2016.1120642","volume":"128","author":"Gasior","year":"2016","journal-title":"Postgrad Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jcph.235","volume":"54","author":"Harris","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1146\/annurev-bioeng-060418-052155","volume":"21","author":"Park","year":"2019","journal-title":"Annu Rev Biomed Eng"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/pmt-2019-0052","volume":"10","author":"Carinci","year":"2020","journal-title":"Pain Manag"},{"key":"ref43","unstructured":"US Food and Drug Administration. Abuse-deterrent opioid analgesics. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/abuse-deterrent-opioid-analgesics. Accessed May 8, 2023."},{"key":"ref44","first-page":"34","volume":"95","author":"Nguyen","year":"2017","journal-title":"Chem. Eng. News"},{"key":"ref45","unstructured":"University of Massachusetts Medical School. Drug formulary commission monograph: oxycodone extended-release (OxyContin\u00ae). Available from: https:\/\/www.mass.gov\/doc\/oxycontin-drug-monograph-amended\/download. Accessed July 24, 2023."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/pm\/pnw208","volume":"18","author":"Harris","year":"2017","journal-title":"Pain Med"},{"key":"ref47","unstructured":"FDA advisory committee briefing document. RoxyBond (TM) (oxycodone hydrochloride) immediate-release tablets. Available from: https:\/\/www.fda.gov\/media\/104339\/download. Accessed July 24, 2023."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5055\/jom.2016.0312","volume":"12","author":"Fleming","year":"2016","journal-title":"J Opioid Manag"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/JMDH.S166915","volume":"11","author":"Adler","year":"2018","journal-title":"J Multidiscip Healthc"},{"key":"ref50","first-page":"82","volume":"114","author":"Hirsch","year":"2017","journal-title":"Mo Med"},{"key":"ref51","unstructured":"US Food and Drug Administration. Timeline of selected FDA activities and significant events addressing substance use and overdose prevention. Available from: https:\/\/www.fda.gov\/drugs\/information-drug-class\/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose. Accessed August 4, 2023."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.drugalcdep.2012.12.006","volume":"131","author":"Cone","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40122-016-0062-1","volume":"5","author":"Gudin","year":"2016","journal-title":"Pain Ther"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s40261-017-0561-9","volume":"37","author":"Mayock","year":"2017","journal-title":"Clin Drug Investig"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.5055\/jom.2018.0468","volume":"14","author":"Meske","year":"2018","journal-title":"J Opioid Manag"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2217\/pmt-2017-0030","volume":"7","author":"Brennan","year":"2017","journal-title":"Pain Manag"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamapsychiatry.2014.3043","volume":"72","author":"Cicero","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1093\/pm\/pnx151","volume":"19","author":"Butler","year":"2018","journal-title":"Pain Med"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2147\/JPR.S304805","volume":"14","author":"Green","year":"2021","journal-title":"J Pain Res"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1093\/pm\/pnaa272","volume":"21","author":"Severtson","year":"2020","journal-title":"Pain Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40261-023-01248-9","volume":"43","author":"Jewell","year":"2023","journal-title":"Clin Drug Investig"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.drugalcdep.2017.01.039","volume":"175","author":"Green","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","volume":"14","author":"Butler","year":"2013","journal-title":"J Pain"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/pme.12834","volume":"16","author":"Gudin","year":"2015","journal-title":"Pain Med"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/jcph.833","volume":"57","author":"Kopecky","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.drugalcdep.2016.06.009","volume":"165","author":"Chilcoat","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/cpt.390","volume":"100","author":"Coplan","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/pds.3723","volume":"24","author":"Hwang","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.jval.2021.04.1274","volume":"24","author":"Khouja","year":"2021","journal-title":"Value Health"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"109933","DOI":"10.1016\/j.drugalcdep.2023.109933","volume":"248","author":"Larochelle","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"e190665","DOI":"10.1001\/jamanetworkopen.2019.0665","volume":"2","author":"Schieber","year":"2019","journal-title":"JAMA Network Open"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare11030437","volume":"11","author":"Sahebi-Fakhrabad","year":"2023","journal-title":"Healthcare"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e2115328","DOI":"10.1001\/jamanetworkopen.2021.15328","volume":"4","author":"Gray","year":"2021","journal-title":"JAMA Network Open"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40122-021-00343-z","volume":"11","author":"Dasgupta","year":"2022","journal-title":"Pain Ther"},{"key":"ref75","unstructured":"US Food and Drug Administration. Opioid analgesic risk evaluation and mitigation strategy(REMS). Available from: https:\/\/www.fda.gov\/drugs\/information-drug-class\/opioid-analgesic-risk-evaluation-and-mitigation-strategy-rems. Accessed July 7, 2023."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/pm\/pnx232","volume":"19","author":"Brooks","year":"2018","journal-title":"Pain Med"},{"key":"ref77","first-page":"21","volume":"13","author":"Petrilla","year":"2020","journal-title":"Am Health Drug Benefits"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.jval.2018.12.005","volume":"22","author":"Kumar","year":"2019","journal-title":"Value Health"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3399\/BJGPO.2022.0085","volume":"6","author":"Gill","year":"2022","journal-title":"BJGP Open"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1097\/ALN.0000000000002031","volume":"128","author":"Litman","year":"2018","journal-title":"Anesthesiology"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/CEOR.S340290","volume":"14","author":"Olatoke","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref82","unstructured":"Ballotpedia. Opioid prescription limits and policies by state. Available from: https:\/\/ballotpedia.org\/Opioid_prescription_limits_and_policies_by_state. Accessed July 7, 2023."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5055\/jom.2017.0405","volume":"13","author":"Passik","year":"2017","journal-title":"J Opioid Manag"},{"key":"ref84","unstructured":"US Center for Disease Control and Prevention. US opioid dispensing rate maps. Available from: https:\/\/www.cdc.gov\/drugoverdose\/rxrate-maps\/index.html.Accessed April 28, 2023."}],"container-title":["Journal of Pain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=99735","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=99735","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T10:02:49Z","timestamp":1717581769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/review-of-opioid-abuse-deterrent-formulations-impact-and-barriers-to-a-peer-reviewed-fulltext-article-JPR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":84,"URL":"https:\/\/doi.org\/10.2147\/jpr.s457982","relation":{},"ISSN":["1178-7090"],"issn-type":[{"value":"1178-7090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6]]}}}